<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1726-8958</journal-id>
<journal-title><![CDATA[Revista Médica La Paz]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. La Paz]]></abbrev-journal-title>
<issn>1726-8958</issn>
<publisher>
<publisher-name><![CDATA[Colegio Médico de La Paz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1726-89582023000200021</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[EVENTOS ADVERSOS DE LA VACUNA SINOPHARM EN ADULTOS EN LA PAZ - BOLIVIA]]></article-title>
<article-title xml:lang="en"><![CDATA[SINOPHARM VACCINE ADVERSE EVENTS IN ADULTS AT LA PAZ-BOLIVIA]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos Magne]]></surname>
<given-names><![CDATA[Paola Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cajias Luna]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Valle postgrado ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Red de Salud Lotes y Servicios Centro de Salud Lotes y Servicios ]]></institution>
<addr-line><![CDATA[El Alto ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>29</volume>
<numero>2</numero>
<fpage>21</fpage>
<lpage>29</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1726-89582023000200021&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1726-89582023000200021&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1726-89582023000200021&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  INTRODUCCIÓN: La vacunación es la única herramienta práctica para detener la expansión y erradicar la pandemia COVID-19, la mayoría de las vacunas han demostrado capacidad de inducir respuestas inmunitarias. Es predecible que existan varias vacunas con distintos niveles de protección por lo que su uso dependerá en cada país de las autoridades sanitarias y recomendaciones de la Organización Mundial de la Salud (OMS).  OBJETIVO: Determinar los Eventos Adversos (ESAVIS) de la vacuna Sinopharm administrada en personas adultas en el punto de vacunación masivo de la Red de salud N°4 ESTE de la ciudad de La Paz, meses de abril a octubre gestión 2021.  MATERIAL Y MÉTODOS: Se realizó un estudio descriptivo, observacional, muestra de 60 casos, con diagnóstico de Eventos Supuestamente atribuibles a la vacunación y/o inmunización. Los métodos empleados fueron análisis documental, instrumentos usados fichas ESAVIS del Ministerio de Salud y Deportes. Se recogieron datos sociodemográficos, sexo y edad.  RESULTADOS: Las personas que presentaron eventos adversos a la Vacuna Sinopharm son del sexo femenino en un 78,3% con un promedio de edad 44 años, con antecedentes patológicos de Hipertensión Arterial Sistèmica en un 5%, el medicamento administrado en un 83,3% es el oxígeno, el síntoma más frecuente son los mareos 58,3%, se presentó más ESAVIS leves en un 98,3%.  CONCLUSIÓN: Las personas que recibieron la vacuna Sinopharm presentan ESAVIS Leves.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  INTRODUCTION: Vaccination is the only practical tool to stop the expansion and eradicate the COVID-19 pandemic, most vaccines have demonstrated the ability to induce immune responses. It is predictable that there are several vaccines with different levels of protection, so their use will depend in each country on the health authorities and recommendations of the World Health Organization (WHO).  OBJECTIVE: To determine the Adverse Events (ESAVIS) of the Sinopharm vaccine administered to adults at the mass vaccination point of the Health Network No. 4 ESTE of the city of La Paz, from April to October, 2021.  MATERIAL AND METHODS: A descriptive, observational study was carried out, a sample of60 cases, with a diagnosis of Events Supposedly attributable to vaccination and/or immunization. The methods used were documentary analysis, instruments used ESAVIS files from the Ministry of Health and Sports. Sociodemographic data, sex and age were collected.  RESULTS: The people who presented adverse events to the Sinopharm Vaccine are 78.3% female with an average age of 44 years, with a pathological history of Systemic Arterial Hypertension in 5%, the medication administered in 83.3% is oxygen, the most frequent symptom is dizziness 58.3%, more mild ESAVIS occurred in 98.3%.  CONCLUSION: People who received the Sinopharm vaccine have Mild ESAVIS.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Vacuna Sinopharm]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV 2]]></kwd>
<kwd lng="es"><![CDATA[antecedentes patológicos]]></kwd>
<kwd lng="en"><![CDATA[Sinopharm vaccine]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV 2]]></kwd>
<kwd lng="en"><![CDATA[pathological background]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Ministerio de Ciencia e Innovacion - España</collab>
<source><![CDATA[Informe Grupo de Trabajo Multidisciplinar (GTM) sobre " Vacunas frente al SARS CoV-2 causante de la COVID-19: Conceptos y desarrollos"]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Espana ]]></publisher-loc>
<publisher-name><![CDATA[GTM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viruez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Molano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tinoco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neumonia por SARS-CoV-2 en cuidados intensivos a tres niveles de altitud en Latinoamerica. Presentacion y desenlace clinico]]></article-title>
<source><![CDATA[Respirar]]></source>
<year>2022</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>07-14</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Secretaria de Salud Republica de Honduras - Departamento de Salud Materno Infantil</collab>
<source><![CDATA[Manual de Normas y Procedimientos del Programa Ampliado de Inmunizacion (PAI) Honduras 2000-2004]]></source>
<year>2000</year>
<publisher-loc><![CDATA[Honduras ]]></publisher-loc>
<publisher-name><![CDATA[Secretaria de Salud de Honduras]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Organizacion Mundial de la Salud</collab>
<source><![CDATA[]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciapponi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguridad y eficacia preliminar de las vacunas para la prevencion de COVID-19]]></article-title>
<source><![CDATA[Rev Evid Actual Pract Ambul]]></source>
<year>2021</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Picazo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vacuna frente al COVID-19]]></article-title>
<source><![CDATA[Rev Esp Quimioter]]></source>
<year>2021</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>569-98</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia de la vacuna Sinopharm contra el COVID-19]]></article-title>
<source><![CDATA[Evid Actual En Practica Ambulatoria]]></source>
<year>2021</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Quan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2020</year>
<volume>182</volume>
<page-range>713-21</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analisis de la Seguridad de las Vacunas contra la COVID-19 en la provincia de Buenos Aires, Argentina]]></article-title>
<source><![CDATA[Rev Argent Med]]></source>
<year>2021</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jahromi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Al Sheikh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Partial protection of Sinopharm vaccine against SARS COV2 during recent outbreak in Bahrain]]></article-title>
<source><![CDATA[Microb Pathog]]></source>
<year>2021</year>
<volume>158</volume>
<numero>September 2021</numero>
<issue>September 2021</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ariamanesh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Porouhan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[PeyroShabany]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fazilat-Panah]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dehghani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nabavifard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy]]></article-title>
<source><![CDATA[Cancer Invest]]></source>
<year>2022</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-34</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>Agencia Estatal de Medicamentos y Tecnologias en Salud - Bolivia</collab>
<source><![CDATA[Socializacion del boletin Estadistico de Eventos Supuestamente Atribuibles a la Vacunacion o Inmunizacion]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bayarre H. Perez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Estudios epidemiologicos descriptivos, Metodos y tecnicas para la investigacion primaria en salud]]></source>
<year>2000</year>
<publisher-name><![CDATA[STUDOCU]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sampieri]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Baptista]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<source><![CDATA[Metodologia de la investigacion]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Mexico ]]></publisher-loc>
<publisher-name><![CDATA[Mc Graw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>DefinicionABC.com</collab>
<source><![CDATA[Definicion de Adulto mayor]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otzen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Manterola]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tecnicas de Muestreo sobre una Poblacion a Estudio]]></article-title>
<source><![CDATA[Int J Morphol]]></source>
<year>2017</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>227-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elementos para el diseno de Tecnicas de Investigacion: una propuesta de definiciones y procedimientos en la Investigacion Cientifica]]></article-title>
<source><![CDATA[Tiempo de Educar]]></source>
<year>2011</year>
<volume>12</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>277-97</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saeed]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Shahrabi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Alhaj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alkokhardi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Adrees]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Side effects and perceptions following Sinopharm COVID-19 vaccination]]></article-title>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2021</year>
<volume>111</volume>
<numero>2021</numero>
<issue>2021</issue>
<page-range>219-26</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2021</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-51</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mezarina-Mendoza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco-Freitas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre-Siancas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobre eventos adversos de la vacuna contra la COVID-19 de Sinopharm]]></article-title>
<source><![CDATA[Rev Chil Infectol]]></source>
<year>2021</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>586-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ghadiri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Azimi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Naser]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2021</year>
<volume>39</volume>
<numero>43</numero>
<issue>43</issue>
<page-range>6347-50</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moghnieh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mekdashi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[El-Hassan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abdallah]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jisr]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bader]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2021</year>
<volume>39</volume>
<numero>46</numero>
<issue>46</issue>
<page-range>6713-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<collab>Instituto de Efectividad Clinica y Sanitaria (IECS)</collab>
<source><![CDATA[Vacunas contra la COVID-19. Documentos de Evaluacion de Tecnologias Sanitarias]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pastrian-Soto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bases Geneticas y Moleculares del COVID-19 (SARS-CoV-2). Mecanismos de Patogenesis y de Respuesta Inmune]]></article-title>
<source><![CDATA[Int J Odontostomatol]]></source>
<year>2020</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>331-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
